Loading…
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma
Summary T‐cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B‐cell lymphoma a...
Saved in:
| Published in: | British journal of haematology 2007-11, Vol.139 (3), p.425-428 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4288-fc01b91f13f61c35088d7929461a951afbbcf15d457fd63936153b82a1bf32ba3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4288-fc01b91f13f61c35088d7929461a951afbbcf15d457fd63936153b82a1bf32ba3 |
| container_end_page | 428 |
| container_issue | 3 |
| container_start_page | 425 |
| container_title | British journal of haematology |
| container_volume | 139 |
| creator | O'Connor, Owen A. Hamlin, Paul A. Portlock, Carol Moskowitz, Craig H. Noy, Ariela Straus, David J. MacGregor‐Cortelli, Barbara Neylon, Ellen Sarasohn, Debra Dumetrescu, Otila Mould, Diane R. Fleischer, Martin Zelenetz, Andrew D. Sirotnak, Frank Horwitz, Steven |
| description | Summary
T‐cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B‐cell lymphoma and four had refractory aggressive TCL. All four patients with TCL achieved a complete remission. Patients with B‐cell lymphoma achieved stable disease at best. For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL. |
| doi_str_mv | 10.1111/j.1365-2141.2007.06658.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68341383</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68341383</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4288-fc01b91f13f61c35088d7929461a951afbbcf15d457fd63936153b82a1bf32ba3</originalsourceid><addsrcrecordid>eNqNkcFu1DAQhiMEokvhFZAvcOounjjxOgcOtAIKqgSHcrYmjk28OHGwk3Zz4xF4O-48CU53RY_gi23N5_n_8Z9lBOgG0nq12wDj5TqHAjY5pdsN5bwUm_2DbPW38DBb0VRaAy3ESfYkxh2lwGgJj7MT2FZAOctX2a_PAR2OQe9x1GcESe9vtCPKYYzEG4L9aI135NaOLWnt15agMba340yMD2RsNQm6mZRu0j010kRhCFaH3z9-jvOgCZyRIfiFiKTD8C2ByneD0wnFviHNFLB2S5fOxmh9H4ntk4_G3ugQF53kQrW680kr4DAn0gRUow9z0or6zuZ1klPaOeLmbmh9h0-zRwZd1M-O-2n25d3b64vL9dWn9x8u3lytVZELsTaKQl2BAWY4KFZSIZptlVcFB6xKQFPXykDZFOXWNJxVjEPJapEj1IblNbLT7OWhbxry-6TjKNMYixPstZ-i5IIVwAT7J5incIQoqgSKA6iCjzENK4dg08_NEqhc0pc7uYQsl5Dlkr68S1_u09PnR42p7nRz__AYdwJeHAGMCl36x17ZeM9VUHLIeeJeH7hb6_T83wbk-cfL5cT-AJpW0TE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20138849</pqid></control><display><type>article</type><title>Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>O'Connor, Owen A. ; Hamlin, Paul A. ; Portlock, Carol ; Moskowitz, Craig H. ; Noy, Ariela ; Straus, David J. ; MacGregor‐Cortelli, Barbara ; Neylon, Ellen ; Sarasohn, Debra ; Dumetrescu, Otila ; Mould, Diane R. ; Fleischer, Martin ; Zelenetz, Andrew D. ; Sirotnak, Frank ; Horwitz, Steven</creator><creatorcontrib>O'Connor, Owen A. ; Hamlin, Paul A. ; Portlock, Carol ; Moskowitz, Craig H. ; Noy, Ariela ; Straus, David J. ; MacGregor‐Cortelli, Barbara ; Neylon, Ellen ; Sarasohn, Debra ; Dumetrescu, Otila ; Mould, Diane R. ; Fleischer, Martin ; Zelenetz, Andrew D. ; Sirotnak, Frank ; Horwitz, Steven</creatorcontrib><description>Summary
T‐cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B‐cell lymphoma and four had refractory aggressive TCL. All four patients with TCL achieved a complete remission. Patients with B‐cell lymphoma achieved stable disease at best. For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/j.1365-2141.2007.06658.x</identifier><identifier>PMID: 17910632</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aminopterin - analogs & derivatives ; Aminopterin - metabolism ; Aminopterin - therapeutic use ; antifolate ; Antineoplastic Agents - metabolism ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Female ; Folic Acid Antagonists - metabolism ; Folic Acid Antagonists - therapeutic use ; Hematologic and hematopoietic diseases ; Humans ; Lymphoma, B-Cell - drug therapy ; Lymphoma, T-Cell - diagnostic imaging ; Lymphoma, T-Cell - drug therapy ; Male ; Medical sciences ; Membrane Transport Proteins - metabolism ; Middle Aged ; Positron-Emission Tomography ; pralatrexate ; reduced folate carrier ; Treatment Failure ; Treatment Outcome ; T‐cell lymphoma</subject><ispartof>British journal of haematology, 2007-11, Vol.139 (3), p.425-428</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4288-fc01b91f13f61c35088d7929461a951afbbcf15d457fd63936153b82a1bf32ba3</citedby><cites>FETCH-LOGICAL-c4288-fc01b91f13f61c35088d7929461a951afbbcf15d457fd63936153b82a1bf32ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19156126$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17910632$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>O'Connor, Owen A.</creatorcontrib><creatorcontrib>Hamlin, Paul A.</creatorcontrib><creatorcontrib>Portlock, Carol</creatorcontrib><creatorcontrib>Moskowitz, Craig H.</creatorcontrib><creatorcontrib>Noy, Ariela</creatorcontrib><creatorcontrib>Straus, David J.</creatorcontrib><creatorcontrib>MacGregor‐Cortelli, Barbara</creatorcontrib><creatorcontrib>Neylon, Ellen</creatorcontrib><creatorcontrib>Sarasohn, Debra</creatorcontrib><creatorcontrib>Dumetrescu, Otila</creatorcontrib><creatorcontrib>Mould, Diane R.</creatorcontrib><creatorcontrib>Fleischer, Martin</creatorcontrib><creatorcontrib>Zelenetz, Andrew D.</creatorcontrib><creatorcontrib>Sirotnak, Frank</creatorcontrib><creatorcontrib>Horwitz, Steven</creatorcontrib><title>Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
T‐cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B‐cell lymphoma and four had refractory aggressive TCL. All four patients with TCL achieved a complete remission. Patients with B‐cell lymphoma achieved stable disease at best. For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL.</description><subject>Adult</subject><subject>Aged</subject><subject>Aminopterin - analogs & derivatives</subject><subject>Aminopterin - metabolism</subject><subject>Aminopterin - therapeutic use</subject><subject>antifolate</subject><subject>Antineoplastic Agents - metabolism</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Folic Acid Antagonists - metabolism</subject><subject>Folic Acid Antagonists - therapeutic use</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Lymphoma, B-Cell - drug therapy</subject><subject>Lymphoma, T-Cell - diagnostic imaging</subject><subject>Lymphoma, T-Cell - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Transport Proteins - metabolism</subject><subject>Middle Aged</subject><subject>Positron-Emission Tomography</subject><subject>pralatrexate</subject><subject>reduced folate carrier</subject><subject>Treatment Failure</subject><subject>Treatment Outcome</subject><subject>T‐cell lymphoma</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqNkcFu1DAQhiMEokvhFZAvcOounjjxOgcOtAIKqgSHcrYmjk28OHGwk3Zz4xF4O-48CU53RY_gi23N5_n_8Z9lBOgG0nq12wDj5TqHAjY5pdsN5bwUm_2DbPW38DBb0VRaAy3ESfYkxh2lwGgJj7MT2FZAOctX2a_PAR2OQe9x1GcESe9vtCPKYYzEG4L9aI135NaOLWnt15agMba340yMD2RsNQm6mZRu0j010kRhCFaH3z9-jvOgCZyRIfiFiKTD8C2ByneD0wnFviHNFLB2S5fOxmh9H4ntk4_G3ugQF53kQrW680kr4DAn0gRUow9z0or6zuZ1klPaOeLmbmh9h0-zRwZd1M-O-2n25d3b64vL9dWn9x8u3lytVZELsTaKQl2BAWY4KFZSIZptlVcFB6xKQFPXykDZFOXWNJxVjEPJapEj1IblNbLT7OWhbxry-6TjKNMYixPstZ-i5IIVwAT7J5incIQoqgSKA6iCjzENK4dg08_NEqhc0pc7uYQsl5Dlkr68S1_u09PnR42p7nRz__AYdwJeHAGMCl36x17ZeM9VUHLIeeJeH7hb6_T83wbk-cfL5cT-AJpW0TE</recordid><startdate>200711</startdate><enddate>200711</enddate><creator>O'Connor, Owen A.</creator><creator>Hamlin, Paul A.</creator><creator>Portlock, Carol</creator><creator>Moskowitz, Craig H.</creator><creator>Noy, Ariela</creator><creator>Straus, David J.</creator><creator>MacGregor‐Cortelli, Barbara</creator><creator>Neylon, Ellen</creator><creator>Sarasohn, Debra</creator><creator>Dumetrescu, Otila</creator><creator>Mould, Diane R.</creator><creator>Fleischer, Martin</creator><creator>Zelenetz, Andrew D.</creator><creator>Sirotnak, Frank</creator><creator>Horwitz, Steven</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200711</creationdate><title>Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma</title><author>O'Connor, Owen A. ; Hamlin, Paul A. ; Portlock, Carol ; Moskowitz, Craig H. ; Noy, Ariela ; Straus, David J. ; MacGregor‐Cortelli, Barbara ; Neylon, Ellen ; Sarasohn, Debra ; Dumetrescu, Otila ; Mould, Diane R. ; Fleischer, Martin ; Zelenetz, Andrew D. ; Sirotnak, Frank ; Horwitz, Steven</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4288-fc01b91f13f61c35088d7929461a951afbbcf15d457fd63936153b82a1bf32ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aminopterin - analogs & derivatives</topic><topic>Aminopterin - metabolism</topic><topic>Aminopterin - therapeutic use</topic><topic>antifolate</topic><topic>Antineoplastic Agents - metabolism</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Folic Acid Antagonists - metabolism</topic><topic>Folic Acid Antagonists - therapeutic use</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Lymphoma, B-Cell - drug therapy</topic><topic>Lymphoma, T-Cell - diagnostic imaging</topic><topic>Lymphoma, T-Cell - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Transport Proteins - metabolism</topic><topic>Middle Aged</topic><topic>Positron-Emission Tomography</topic><topic>pralatrexate</topic><topic>reduced folate carrier</topic><topic>Treatment Failure</topic><topic>Treatment Outcome</topic><topic>T‐cell lymphoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'Connor, Owen A.</creatorcontrib><creatorcontrib>Hamlin, Paul A.</creatorcontrib><creatorcontrib>Portlock, Carol</creatorcontrib><creatorcontrib>Moskowitz, Craig H.</creatorcontrib><creatorcontrib>Noy, Ariela</creatorcontrib><creatorcontrib>Straus, David J.</creatorcontrib><creatorcontrib>MacGregor‐Cortelli, Barbara</creatorcontrib><creatorcontrib>Neylon, Ellen</creatorcontrib><creatorcontrib>Sarasohn, Debra</creatorcontrib><creatorcontrib>Dumetrescu, Otila</creatorcontrib><creatorcontrib>Mould, Diane R.</creatorcontrib><creatorcontrib>Fleischer, Martin</creatorcontrib><creatorcontrib>Zelenetz, Andrew D.</creatorcontrib><creatorcontrib>Sirotnak, Frank</creatorcontrib><creatorcontrib>Horwitz, Steven</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'Connor, Owen A.</au><au>Hamlin, Paul A.</au><au>Portlock, Carol</au><au>Moskowitz, Craig H.</au><au>Noy, Ariela</au><au>Straus, David J.</au><au>MacGregor‐Cortelli, Barbara</au><au>Neylon, Ellen</au><au>Sarasohn, Debra</au><au>Dumetrescu, Otila</au><au>Mould, Diane R.</au><au>Fleischer, Martin</au><au>Zelenetz, Andrew D.</au><au>Sirotnak, Frank</au><au>Horwitz, Steven</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2007-11</date><risdate>2007</risdate><volume>139</volume><issue>3</issue><spage>425</spage><epage>428</epage><pages>425-428</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>Summary
T‐cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B‐cell lymphoma and four had refractory aggressive TCL. All four patients with TCL achieved a complete remission. Patients with B‐cell lymphoma achieved stable disease at best. For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17910632</pmid><doi>10.1111/j.1365-2141.2007.06658.x</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2007-11, Vol.139 (3), p.425-428 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68341383 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult Aged Aminopterin - analogs & derivatives Aminopterin - metabolism Aminopterin - therapeutic use antifolate Antineoplastic Agents - metabolism Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Female Folic Acid Antagonists - metabolism Folic Acid Antagonists - therapeutic use Hematologic and hematopoietic diseases Humans Lymphoma, B-Cell - drug therapy Lymphoma, T-Cell - diagnostic imaging Lymphoma, T-Cell - drug therapy Male Medical sciences Membrane Transport Proteins - metabolism Middle Aged Positron-Emission Tomography pralatrexate reduced folate carrier Treatment Failure Treatment Outcome T‐cell lymphoma |
| title | Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T10%3A11%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pralatrexate,%20a%20novel%20class%20of%20antifol%20with%20high%20affinity%20for%20the%20reduced%20folate%20carrier%E2%80%90type%201,%20produces%20marked%20complete%20and%20durable%20remissions%20in%20a%20diversity%20of%20chemotherapy%20refractory%20cases%20of%20T%E2%80%90cell%20lymphoma&rft.jtitle=British%20journal%20of%20haematology&rft.au=O'Connor,%20Owen%20A.&rft.date=2007-11&rft.volume=139&rft.issue=3&rft.spage=425&rft.epage=428&rft.pages=425-428&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1111/j.1365-2141.2007.06658.x&rft_dat=%3Cproquest_cross%3E68341383%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4288-fc01b91f13f61c35088d7929461a951afbbcf15d457fd63936153b82a1bf32ba3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20138849&rft_id=info:pmid/17910632&rfr_iscdi=true |